News and Trends 28 Jan 2019 Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents Update (01/02/2019): MorphoSys has agreed to end its long-running legal battle with Genmab and Janssen, after the US District Court of Delaware declared three of its cancer immunotherapy patents invalid. MorphoSys began the dispute over Darzalex (daratumumab), Genmab and Janssen’s approved antibody therapy for the blood cancer multiple myeloma. MorphoSys alleged that Darzalex infringed on three of […] January 28, 2019 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 19 Nov 2016 Looking for outperforming cell lines ? CHOvolution is an all-in-one kit for GMP Bioproduction For any drug developer or service provider, cell line development is one of the most challenging phases, especially when subsequent GMP compliance is required. The need to secure good cell lines can, therefore, make all the difference in getting any biological to the market. The Swiss company Celonic has produced CHOvolution™, a cell line kit that allows you to […] November 19, 2016 - 4 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2016 UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug Sanofi and Regeneron (NY, US) have ruled their phase III clinical trial immunotherapy Sarilumab a huge success. Now awaiting US FDA and EMA approval, the results from the latest study were presented at the American College of Rheumatology (ACR) annual meeting in San Francisco. Should Sarilumab be approved, this immunotherapy will be used to treat […] October 31, 2016 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2016 UPDATE: Immuno-Oncology Combo works on Lung Cancer Regardless of PD-L1 Type AstraZeneca’s MedImmune (UK) has published phase Ib study results in The Lancet Oncology. These showed anti-tumour activity of a combination of investigational antibodies in patients with lung cancer. The trial considered patients undergoing treatment with durvalumab and tremelimumab, to see whether the drug combo could act therapeuticaly against locally advanced or metastatic non-small cell lung cancer (NSCLC), irrespective of […] October 28, 2016 - 2 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2016 What is Lithuania’s role in European Biotech? Since the days of the Soviet Union, Lithuania has always been considered as a leader in life sciences discoveries in Eastern Europe due to its infrastructure. But what about for Biotech? Nowadays, as a member of the NATO, the European Union, and Eurozone, Lithuania’s life science sector is growing around 20-25% annually; with special focus on […] July 26, 2016 - 2 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 11 Feb 2016 Sanofi-Genzyme: Still successful 5 years after the acquisition? Back in 2011, France’s biggest Pharmaceutical company Sanofi decided to purchase Genzyme Corp. for more than $20 billion, thus becoming the latest global drug giant to acquire a big biotech to foster its R&D pipeline. 5 years later, what’s the situation for Genzyme and Sanofi? So often when a large Pharma acquires a smaller Biotech, […] February 11, 2016 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2015 Synbio Perfumery: Making Smells and Flavors with Microbes Isobionics is a biotech from the Netherlands that specializes in synthetic bio-production of natural essential oils and flavorings for use in the food, perfume and detergent industry. On the other hand, Evolva, from Basel, are estimated to produce up to $500M worth of synthetic vanilla essence for the industry each year. Using bacteria and yeast […] October 19, 2015 - 4 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email